The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab

Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab

December 19, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

These approvals were based on the Phase 3, GO-VIBRANT and GO-ALIVE studies. Both studies were multicenter, randomized, double blind and placebo controlled.

You Might Also Like
  • Bisphosphonate Drug Holiday & Hip Fracture Risk
  • Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA
  • Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept
Explore This Issue
December 2017
Also By This Author
  • FDA Update: New Boxed Warnings for Opioids & Benzodiazepines; Plus New Drug Safety Labeling Changes Database

In late October, the FDA approved golimumab to treat adults with active psoriatic arthritis or active ankylosing spondylitis.

GO-VIBRANT examined golimumab in biologic-naive adults with active PsA (n=480). Patients received 2 mg/kg golimumab at Weeks 0, 4 and then every eight weeks, or placebo at Weeks 0, 4, 12 and 20. Placebo-treated patients crossed over to receive golimumab at Week 24. The primary endpoint was achieving an ACR20 response at Week 14.

GO-ALIVE studied 208 patients with AS who received 2 mg/kg golimumab at Weeks 0, 4 and then every eight weeks or placebo at Weeks 0, 4 and 12. In this study, placebo-treated patients crossed over to receive golimumab at Week 16. The Assessment of Spondyloarthritis International Society criteria (ASAS20) response at Week 16 was the primary endpoint.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In GO-VIBRANT, 75% of golimumab-treated patients vs. 22% of placebo-treated patients attained ACR20 at Week 14. In GO-ALIVE, 73% of golimumab-treated patients vs. 26% placebo-treated patients attained ASAS20 at Week 16. Both responses were considered statistically significant.

Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis

Also in October, the FDA expanded the use of ustekinumab (Stelara) to include a new indication: the treatment of adolescents (patients 12 years of age or older) with moderate to severe plaque psoriasis and who are candidates for phototherapy or systemic therapy.3 Ustekinumab is a fully human interleukin (IL) 12 and IL-23 antagonist, which is administered subcutaneously at Weeks 0 and 4, and every 12 weeks thereafter.

This approval is based on data from a Phase 3 study that evaluated the efficacy and safety of subcutaneous ustekinumab in this patient age group. By Week 12 of the study, at least two-thirds of ustekinumab-treated patients reached the primary endpoint, which was the achievement of a Physician’s Global Assessment (PGA) score of 0 or 1, indicating cleared or minimal psoriasis. These results were reached after just two doses were administered, at Weeks 0 and 4.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The safety findings in adolescents were similar to those seen in adult clinical trials for the treatment of plaque psoriasis. R


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Curtis JR, Chen R, Li Z, et al. The impact of the duration of bisphosphonate drug holidays on hip fracture rates [abstract]. Arthritis Rheumatol. 2017; 69(suppl 10).
  2. Janssen Global Services LLC. Janssen receives two US FDA approvals for Simponi Aria (golimumab) for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis. 2017 Oct 20.
  3. Janssen Pharmaceutical Companies. News release: Janssen announces U.S. FDA approval of Stelara (ustekinumab) for the treatment of adolescents with moderate to severe plaque psoriasis. 2017 Oct 13.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates, Spondyloarthritis Tagged With: Ankylosing Spondylitis, Approval, Bisphosphonate, bone loss, drug therapy, FDA, Fractures, Golimumab, hip, Osteoporosis, osteoporosis treatments, outcome, patient care, plaque psoriasis, Research, rheumatology, risk, Safety, ustekinumab, warningIssue: December 2017

You Might Also Like:
  • Bisphosphonate Drug Holiday & Hip Fracture Risk
  • Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA
  • Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept
  • Rheumatology Drug Updates

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)